Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents

In the current investigation, a new class of quinazolinone N-acetohydrazides 9a-v was designed as type II multi-kinase inhibitors. The target quinazolinones were tailored so that the quinazolinone moiety would occupy the front pocket of the binding sites of VEGFR-2, FGFR-1 and BRAF kinases, meanwhile, the phenyl group at position 2 would act as a spacer which was functionalized at position 4 with an N-acetohydrazide linker that could achieve the key interactions with the essential gate area amino acids. The hydrazide moiety was linked to diverse aryl derivatives to occupy the hydrophobic back pocket of the DFG-out conformation of target kinases. The synthesized quinazolinone derivatives 9a-v demonstrated moderate to potent VEGFR-2 inhibitory activity with IC50 spanning from 0.29 to 5.17?µM. Further evaluation of the most potent derivatives on FGFR-1, BRAFwt and BRAFV600E showed that the quinazolinone N-acetohydrazides 9d, 9e, 9f, 9?L and 9?m have a potent multi-kinase inhibitory activity. Concurrently, 9b, 9d, 9e, 9?k, 9?L, 9o, 9q demonstrated potent mean growth inhibitory activity on NCI cancer cell lines with GI50 reaching 0.72?µM. In addition, compound 9e arrested the cell cycle progression in MDA-MB-231 cell line at the G2/M phase and showed the ability to induce apoptosis.